Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial. - sprookjes - yvandenbroek - TriplyDB

Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial.

Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial.

http://www.wikidata.org/entity/Q35159258

about

An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A Ascorbic acid for the treatment of Charcot-Marie-Tooth disease Interventions for fatigue in peripheral neuropathy Management of Charcot-Marie-Tooth disease: improving long-term care with a multidisciplinary approach The genetics of Charcot-Marie-Tooth disease: current trends and future implications for diagnosis and management Charcot-Marie-Tooth disease and intracellular traffic Regulation of the Epigenome by Vitamin C Guidance in social and ethical issues related to clinical, diagnostic care and novel therapies for hereditary neuromuscular rare diseases: "translating" the translational Haplotype-specific modulation of a SOX10/CREB response element at the Charcot-Marie-Tooth disease type 4C locus SH3TC2.Psychometrics evaluation of Charcot-Marie-Tooth Neuropathy Score (CMTNSv2) second version, using Rasch analysis.Quality of life and measures of quality of life in patients with neuromuscular disorders.Validation of the Charcot-Marie-Tooth disease pediatric scale as an outcome measure of disability.Reliability of the CMT neuropathy score (second version) in Charcot-Marie-Tooth disease.MRI biomarker assessment of neuromuscular disease progression: a prospective observational cohort study.Reproducibility, and age, body-weight and gender dependency of candidate skeletal muscle MRI outcome measures in healthy volunteers.Iron homeostasis in peripheral nervous system, still a black box?The PMP22 gene and its related diseases.Proximal nerve magnetization transfer MRI relates to disability in Charcot-Marie-Tooth diseases Quality-of-life in Charcot-Marie-Tooth disease: the patient's perspective.Axonal Charcot-Marie-Tooth disease patient-derived motor neurons demonstrate disease-specific phenotypes including abnormal electrophysiological properties.Colony-stimulating factor-1 mediates macrophage-related neural damage in a model for Charcot-Marie-Tooth disease type 1X CMT subtypes and disease burden in patients enrolled in the Inherited Neuropathies Consortium natural history study: a cross-sectional analysis.Identification of drug modulators targeting gene-dosage disease CMT1A.A Rasch Analysis of the Charcot-Marie-Tooth Neuropathy Score (CMTNS) in a Cohort of Charcot-Marie-Tooth Type 1A Patients Plasma metabolome and skin proteins in Charcot-Marie-Tooth 1A patients Reevaluating measures of disease progression in facioscapulohumeral muscular dystrophy Vitamin C and Charcot-Marie-Tooth 1A: Pharmacokinetic considerations.Anterior tibialis CMAP amplitude correlations with impairment in CMT1A.Inherited peripheral neuropathies.Changes of gait pattern in children with Charcot-Marie-Tooth disease type 1A: a 18 months follow-up study.Transitioning outcome measures: relationship between the CMTPedS and CMTNSv2 in children, adolescents, and young adults with Charcot-Marie-Tooth disease.Charcot-Marie-Tooth disease: frequency of genetic subtypes and guidelines for genetic testing.High-dosage ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A: results of a randomized, double-masked, controlled trial Metabolite profile of a mouse model of Charcot-Marie-Tooth type 2D neuropathy: implications for disease mechanisms and interventions.Distal Symmetric Polyneuropathy: A Review.Outcome measures for Charcot-Marie-Tooth disease: clinical and neurofunctional assessment in children.Inherited neuropathies: clinical overview and update.PMP22 related neuropathies: Charcot-Marie-Tooth disease type 1A and Hereditary Neuropathy with liability to Pressure Palsies.Murine therapeutic models for Charcot-Marie-Tooth (CMT) disease.Neural and molecular features on Charcot-Marie-Tooth disease plasticity and therapy.

P2860

Q22000603-8266DA9D-ACA0-4F0E-9B61-D6EE7CB917EB Q24187132-2026003D-BDBC-4CAC-823C-FC4BA702BC9B Q24187233-54449C27-4B5D-4725-B06A-2EF309846DCA Q26768401-3D832B5D-79C0-43A6-87BD-D99F86186BBE Q26777319-7F36E376-725B-4B7C-A9C2-36F45444014F Q26824841-31F13F38-7EEC-48BC-95BF-179A408611FC Q27000867-6667D696-EAB3-4EF5-8DB2-7D6162647B34 Q28485060-C20B62F3-0F06-46B4-AF7D-675096E07A9D Q30009423-36DEDBF6-CF28-46E0-ADCE-9C2DF5D88123 Q30301300-A89B4B2A-4C5A-4285-87DD-AAE0BA356A57 Q30455590-F054E1AD-BF90-49AD-AA6D-A3FEB13A0229 Q30513760-2C78F79D-48DF-4C73-BA14-59F4087843D7 Q30543772-32AEB863-43AF-440B-B2E4-976535E013F8 Q31019878-41991FB2-8B6E-4F17-9483-5E51629378DF Q33713240-B54975D3-F170-4DCF-9672-1130C152036A Q33860305-6BB67FE6-9B77-4752-A613-1071952DF1A3 Q34316615-B39897D9-75FD-476F-A922-6875CD681E48 Q34465428-A739C2E9-77AA-4FBC-AB90-5BA596A5C9AA Q34621607-F683B614-2724-47DC-9541-419C4AA8B9A1 Q34674307-C6247A29-F416-4412-B53C-DB1D78F58334 Q35706394-A385C63F-BCB5-49E8-9D46-DD9932B0EEDE Q35891892-6B35AAE4-52E1-4EFE-9240-0C6B126686FD Q36106700-4CD62FC0-09D9-4512-8762-06CE1DF20E22 Q36251291-E3F46A03-25E6-4987-AE25-353111474BA7 Q36390813-A0E70571-6CD2-410E-89BB-6F71AC98B3CC Q36698443-F56B2F91-B1CE-43D7-BFC4-D3736AD017B1 Q36701520-425015EC-5FDA-4207-8F45-1DA7EE56E658 Q36717951-9D49D3D8-9E40-414E-8307-85EF8795A575 Q36822088-6B2DC6AD-AEC4-4280-A4D2-728C2E1567F0 Q37000938-B31DB037-49E2-4795-8124-35284E445217 Q37021766-2074F8DF-71E4-44AF-8D2F-8DBC192E9DE8 Q37078644-C0175A03-B1F0-4ED1-9393-7E3CDA6B9948 Q37118241-5C9F60EE-4BE8-4A11-8FB7-3D3151FF4AAE Q37120323-B56EFB83-5392-4FC3-B61D-B0947053118C Q37444601-8E33326C-E592-43DB-91DC-06BEE6907FE4 Q37565640-13418456-D4C7-4A9C-9911-C1BCA78A31EC Q37571617-EE32AA6C-1ADA-4DAD-A714-0D2F62CBE805 Q37715520-D2F79638-5D00-4844-8FB1-21FCD9A3B749 Q38007033-833CB25D-A94D-459C-AD2D-68DDD4FCAB7F Q38022624-9734CC72-735E-4A14-BEAF-7789FE41B2AA

P2860

Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial.

http://www.wikidata.org/entity/Q35159258

description

2011 nî lūn-bûn

@nan

2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Ascorbic acid in Charcot-Marie ...... double-blind randomised trial.

@ast

Ascorbic acid in Charcot-Marie ...... double-blind randomised trial.

@en

type

label

Ascorbic acid in Charcot-Marie ...... double-blind randomised trial.

@ast

Ascorbic acid in Charcot-Marie ...... double-blind randomised trial.

@en

prefLabel

Ascorbic acid in Charcot-Marie ...... double-blind randomised trial.

@ast

Ascorbic acid in Charcot-Marie ...... double-blind randomised trial.

@en

P1433

Q35159258-3EC29124-509D-4A2C-8A91-84FDF858CD19

P1476

Q35159258-44822260-6CF9-4D42-8912-896AFB64A42E

P2093

Q35159258-0A4E1FE0-F156-4D92-B68F-FA00D07A1BBD

Q35159258-116175E0-B88F-4874-A5BB-484FA874B450

Q35159258-157F412C-CEB5-44B5-AC40-2FA2128DA5DB

Q35159258-3AD0C58E-9A71-4EDB-A3F9-64A37B981C65

Q35159258-8EC7AE68-90FF-4CB8-A9FE-0E7336850D80

Q35159258-8F6D0D92-690F-4247-9D90-F65F3273C2B8

Q35159258-A10402CF-CC5D-49E4-8130-C4296AB42EB4

Q35159258-A107D24C-7C36-4EA2-B004-E289DD3FA996

Q35159258-A63860CE-BE81-4690-BD67-86B068F78727

Q35159258-D2992447-D986-43EE-94AE-1A66CA9BAE78

P2860

Q35159258-03051894-3775-47B4-9D67-B0661DD5A8E4

Q35159258-119B6E5C-F0F7-4774-9B6E-ED02E7E3A03F

Q35159258-24BBBB77-43C9-43C0-A007-91B11A664E7A

Q35159258-330DE239-7CC0-4E8A-9836-767D62A29B92

Q35159258-421212C1-7972-4085-BBDE-6BC243919047

Q35159258-46BF5201-018F-43EF-A644-F4B9FA900E8D

Q35159258-4FDD5380-3E8C-409E-8C0C-34E14797A3EA

Q35159258-5A5ADE2A-6443-4D60-B0D7-AD5F70B2BEF1

Q35159258-619DA774-D93E-495A-924D-A37994F7E1BF

Q35159258-645E8B1A-D32D-4FC5-B3F5-F694ED4942B6

P304

Q35159258-2A5CE74E-41A1-44C2-9421-1CD1A2BCB0B6

P31

Q35159258-AB3F06D2-2D96-4861-B98A-6755A1353BD5

P356

Q35159258-91A6B902-04B1-4B56-B200-775549F69036

P433

Q35159258-542CDA45-C840-4DA5-9F5E-EC79F813DFE7

P478

Q35159258-0ECDDDF4-2F07-4C07-9946-B8FDA3024726

P50

Q35159258-2328100E-098A-4BB4-8A57-24F2E8A20B1D

Q35159258-A3FA7695-FD1C-4E34-AAA2-DDF8DB5B4BE2

Q35159258-E0962368-F6DF-4F5A-ACF7-8AEC8B67AC3C

Q35159258-E83642C5-EF9D-4AB5-926C-B1C2BA30BEEE

P577

Q35159258-5B015BA2-4AC3-472B-96D7-851F745384F2

P698

Q35159258-0461D1F1-AB43-4307-9DC3-0972A25CA140

P932

Q35159258-B25ED6EA-83CC-4C65-9DBD-098F34E31D1C

P356

S1474-4422(11)70025-4

P1433

Lancet Neurology

P1476

Ascorbic acid in Charcot-Marie ...... double-blind randomised trial.

@en

P2093

Alessandra Solari

http://www.w3.org/2001/XMLSchema#string

Angelo Schenone

http://www.w3.org/2001/XMLSchema#string

CMT-TRAUK groups

http://www.w3.org/2001/XMLSchema#string

CMT-TRIAAL

http://www.w3.org/2001/XMLSchema#string

Daniela Calabrese

http://www.w3.org/2001/XMLSchema#string

Davide Pareyson

http://www.w3.org/2001/XMLSchema#string

Davide Radice

http://www.w3.org/2001/XMLSchema#string

Franco Gemignani

http://www.w3.org/2001/XMLSchema#string

Gian Maria Fabrizi

http://www.w3.org/2001/XMLSchema#string

Luca Padua

http://www.w3.org/2001/XMLSchema#string

P2860

Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance

The MOS 36-ltem Short-Form Health Survey (SF-36)

Diagnosis, natural history, and management of Charcot–Marie–Tooth disease

Oral high dose ascorbic acid treatment for one year in young CMT1A patients: a randomised, double-blind, placebo-controlled phase II trial

Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease.

A modified peripheral neuropathy scale: the Overall Neuropathy Limitations Scale.

Assessment of chronic pain. I. Aspects of the reliability and validity of the visual analogue scale.

Ascorbic acid inhibits PMP22 expression by reducing cAMP levels.

The methanol method for the quantification of ascorbic acid and dehydroascorbic acid in biological samples.

Effect of ascorbic acid in patients with Charcot-Marie-Tooth disease type 1A: a multicentre, randomised, double-blind, placebo-controlled trial.

P304

320-328

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S1474-4422(11)70025-4

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

Francesco Visioli

P577

2011-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21393063

http://www.w3.org/2001/XMLSchema#string

P932

3154498

http://www.w3.org/2001/XMLSchema#string